柴胡疏肝散联合恩替卡韦分散片治疗慢性乙型肝炎肝郁气滞证患者的效果  

Effects of Chaihu Shugan powder combined with Entecavir Dispersible Tablets in treatment of chronic hepatitis B patients with liver qi stagnation syndrome

作　　者：何赠彩 HE Zengcai(Yugan County Schistosomiasis Control Station,Shangrao 335100 Jiangxi,China)

机构地区：[1]余干县血吸虫病防治站,江西上饶335100

出　　处：《中国民康医学》2023年第18期119-121,共3页Medical Journal of Chinese People’s Health

摘　　要：目的:观察柴胡疏肝散联合恩替卡韦分散片治疗慢性乙型肝炎肝郁气滞证患者的效果。方法:选取2022年1月至2023年2月该院收治的72例慢性乙型肝炎肝郁气滞证患者进行前瞻性研究,按随机数字表法将其分为对照组和研究组各36例。对照组采用恩替卡韦分散片治疗,研究组在对照组基础上采用柴胡疏肝散治疗,比较两组临床疗效、治疗前后中医证候积分、肝纤维化指标[透明质酸(HA)、层粘连蛋白(LN)、Ⅳ型胶原(Col-IV)]水平及不良反应发生率。结果:研究组治疗总有效率为83.33%(30/36),高于对照组的61.11%(22/36),差异有统计学意义(P<0.05);治疗后,两组胁痛、太息、胸闷等中医证候积分均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);治疗后,两组血清HA、LN、Col-IV水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:柴胡疏肝散联合恩替卡韦分散片治疗慢性乙型肝炎肝郁气滞证患者可提高治疗总有效率,降低中医证候积分和肝纤维化指标水平,效果优于单纯恩替卡韦分散片治疗。Objective:To observe effects of Chaihu Shugan powder combined with Entecavir Dispersible Tablets in the treatment of chronic hepatitis B patients with liver qi stagnation syndrome.Methods:A prospective study was conducted on 72 patients with chronic hepatitis B with liver qi stagnation syndrome admitted to this hospital from January 2022 to February 2023.They were divided into control group and study group according to the random number table method,36 cases in each group.The control group was treated with Entecavir Dispersible Tablets,while the study group was treated with Chaihu Shugan powder on the basis of that of the control group.The clinical efficacy,the TCM syndrome score,the liver fibrosis indexes[hyaluronic acid(HA),laminin(LN),type IV collagen(Col-IV)]levels before and after the treatment,and incidence of adverse reactions were compared between the two groups.Results:The total effective rate of treatment in the study group was 83.33%(30/36),which was higher than 61.11%(22/36)in the control group,and the difference was statistically significant(P<0.05).After the treatment,the scores of TCM syndromes such as hypochondriac pain,sigh and chest tightness in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of serum HA,LN and Col-IV in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Chaihu Shugan powder combined with Entecavir Dispersible Tablets in the treatment of the chronic hepatitis B patients with liver qi stagnation syndrome can improve the total effective rate of treatment and reduce the TCM syndrome scores and the liver fibrosis index levels.over,it is superior to single Entecavi

关 键 词：慢性乙型肝炎 柴胡疏肝散 恩替卡韦分散片 中医证候积分 肝纤维化 不良反应 

分 类 号：R512.6[医药卫生—内科学]